Skip to main content

Aurora Spine Announces Participation in 7th Annual American Society of Pain & Neuroscience Conference

Written by Customer Service on . Posted in Public Companies.

CARLSBAD, California, July 15, 2025 (GLOBE NEWSWIRE) — Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a leader in innovative spine and interventional pain management solutions, today announced it will be participating in the 7th Annual ASPN Conference sponsored by The American Society of Pain Neuroscience (ASPN) to be held July 17-20 at the Fontainebleu Miami Hotel in Miami Beach, Florida. Aurora will be located at Booth 129/130.

To kick off the first full day of the conference (July 18th), there will be a series of discussions starting with a General Session on ‘Embracing Disruption, Driving Innovation. Minimally Invasive Spine.’ Within this General Session, there will be two discussions with relevancy to Aurora Spine products: Surgical Approaches to Facet Disease and Posterior Approaches to Lumbar Spine and SI Joint.

On Saturday, July 19th, Aurora’s ZIP product series will be highlighted in an ASPN Top Abstract discussion, of which only 12 are selected out of 330 papers that were submitted. Steven Falowski, MD, will deliver the podium talk to discuss: Functional Outcomes in the Low Back Pain Subject with a Novel Interspinous Fusion Device: REFINE Study 12 Month Results.

Later that day, Aurora Spine will be sponsoring the ASPN Charity Reception with beneficiaries being the IRONMAN Foundation and Return to Duty.

“We are very excited about this year’s ASPN Conference, especially having been selected for a podium talk that highlights our ZIP series of products. We are extremely honored to be selected for this discussion, as there are only a few spots for selection,” said Trent Northcutt, President and CEO of Aurora Spine. “We are also excited about this year’s ASPN Conference as we’ll be introducing our AERO Lumbar Fusion System to industry professionals in attendance, which will include in excess of 3,000 industry professionals including neuro, ortho and pain interventionalists.”

For more information about the conference go to: ASPN Annual Conference July 2025.

About Aurora Spine

Aurora Spine is focused on bringing new solutions to the spinal implant market through a series of proprietary, minimally invasive, and regenerative technologies. The company is committed to improving surgical outcomes through innovation, efficiency, and patient-centered design.

For more information, visit: www.aurora-spine.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains forward-looking information that involves substantial known and unknown risks and uncertainties, many of which are beyond Aurora Spine’s control. Forward-looking statements include, but are not limited to, statements regarding the expected use and success of the Company’s products, including the AERO Lumbar Fusion System. Actual results may differ materially. Please refer to Aurora Spine’s final prospectus and public filings for additional information on risks and uncertainties.
These forward-looking statements speak only as of the date of this release. Aurora Spine undertakes no obligation to revise or update them to reflect future events or circumstances.

Contacts:
Aurora Spine Corporation
Trent Northcutt
President and Chief Executive Officer
(760) 424-2004

Chad Clouse
Chief Financial Officer
(760) 424-2004
www.aurora-spine.com

Investor Contact:
Adam Lowensteiner
Lytham Partners
(646) 829-9702
Email: asapf@lythampartners.com

 

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.